Cannabinoid drugs for neurological diseases: What is behind?;Fármacos cannabinoides para las enfermedades neurológicas: ¿qué hay detrás?

Revista de Neurologia

Volumn 54, Issue 10, 2012, Pages 613-628

  Fernández Ruiz, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoid drugs; Cannabinoids; CB1 receptors; CB2 receptors; Endogenous cannabinoid system; Neurological diseases

Indexed keywords

CANNABINOID; DRONABINOL; NABILONE; NABIXIMOLS;

ANOREXIA; ANOREXIA CACHEXIA SYNDROME; CACHEXIA; DRUG EFFICACY; DRUG INDUSTRY; DRUG INHIBITION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MEDICINAL PLANT; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; REVIEW;

EID: 84862208030     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5410.2011689     Document Type: Review

References (74)

1. Ramos JA, Fernández-Ruiz JJ. Uso de los cannabinoides a través de la historia. Monografía Cannabis (Adicciones) 2000; 12: 19-30.
2. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89: 309-80.
3. Trigo JM, Martín-García E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend 2010; 108: 183-94.
4. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 receptors. Pharmacol Rev 2010; 62: 588-631.
5. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008; 184: 435-77.
6. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009; 32: 421-31.
7. De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009; 23: 1-15.
8. Mechoulam R, Lander N, Srebnik M, Breuer A, Segal M, Feigenbaum JJ, et al. Stereochemical requirements for cannabimimetic activity. NIDA Res Monogr 1987; 79: 15-30.
9. Seltzman HH. Structure and receptor activity for classical cannabinoids. Curr Med Chem 1999; 6: 685-704.
10. Howlett AC, Johnson MR, Melvin LS. Classical and nonclassical cannabinoids: mechanism of action-brain binding. NIDA Res Monogr 1990; 96: 100-11.
11. Howlett AC. Regulation of adenylate cyclase in a cultured neuronal cell line by marijuana constituents, metabolites of delta-9-tetrahydrocannabinol, and synthetic analogs having psychoactivity. NIDA Res Monogr 1987; 79: 148-57.
12. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
13. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al., Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
14. Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 2010; 80: 1-12.
15. Gómez-Ruiz M, Hernández M, De Miguel R, Ramos JA. An overview on the biochemistry of the cannabinoid system. Mol Neurobiol 2007; 36: 3-14.
16. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009; 71: 283-306.
17. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009; 60: 77-84.
18. Orgado JM, Fernández-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. Int Rev Psychiatry 2009; 21: 172-80.
19. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008; 13: 147-59.
20. Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010; 15: 474-83.
21. Graham ES, Ashton JC, Glass M. Cannabinoid receptors: a brief history and 'what's hot'. Front Biosci 2009; 14: 944-57.
22. Marrs W, Stella N. Measuring endocannabinoid hydrolysis: refining our tools and understanding. AAPS J 2009; 11: 307-11.
23. Yates ML, Barker EL. Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol Pharmacol 2009; 76: 11-7.
24. Di Marzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006; 57: 553-74.
25. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325.
26. Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 2008; 153: 277-85.
27. Hashimotodani Y, Ohno-Shosaku T, Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007; 13: 127-37.
28. Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry 2009; 21: 113-21.
29. Dalton GD, Bass CE, Van Horn CG, Howlett AC. Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 2009; 8: 422-31.
30. Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 2010; 44: 75-85.
31. Ferré S, Navarro G, Casadó V, Cortés A, Mallol J, Canela EI, et al. G protein-coupled receptor heteromers as new targets for drug development. Prog Mol Biol Transl Sci 2010; 91: 41-52.
32. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 2009; 11: e3.
33. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009; 30: 156-63.
34. Tóth A, Blumberg PM, Boczán J. Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 2009; 81: 389-419.
35. De Petrocellis L, Di Marzo V. Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci 2005; 77: 1651-66.
36. Pistis M, Melis M. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem 2010; 17: 1450-67.
37. Downer EJ. Cannabinoids and innate immunity: taking a toll on neuroinflammation. Sci World J 2011; 11: 855-65.
38. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
39. Ueda N, Tsuboi K, Uyama T, Ohnishi T. Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. Biofactors 2011; 37: 1-7.
40. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98: 3662-5.
41. Hu SS, Bradshaw HB, Benton VM, Chen JS, Huang SM, Minassi A, et al. The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 291-301.
42. Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 1999; 6: 757-73.
43. Ho WS, Hillard CJ. Modulators of endocannabinoid enzymic hydrolysis and membrane transport. Handb Exp Pharmacol 2005; 168: 187-207.
44. Ueda N, Tsuboi K, Uyama T. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res 2010; 49: 299-315.
45. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Invest Drugs 2010; 11: 51-62.
46. Savinainen JR, Saario SM, Laitinen JT. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf) 2011; doi: 10.1111/j.1748-1716.2011.02280.x.
47. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009; 156: 1029-40.
48. Marsicano G, Lafenêtre P. Roles of the endocannabinoid system in learning and memory. Curr Top Behav Neurosci 2009; 1: 201-30.
49. Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 2009; 21: 163-71.
50. Rawls SM, Benamar K. Effects of opioids, cannabinoids, and vanilloids on body temperature. Front Biosci 2011; 3: 822-45.
51. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 2007; 7: 575-82.
52. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009; 6: 713-37.
53. Steiner MA, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008; 170: 397-432.
54. Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, De Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 2010; 14: 387-404.
55. Harkany T, Guzmán M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 2007; 28: 83-92.
56. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006; 46: 101-22.
57. Fernández-Ruiz J, González S. Cannabinoid control function at the basal ganglia. Hand Exp Pharm 2005; 168: 479-507.
58. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 2006; 40: 251-60.
59. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 2010; 10: 80-6.
60. Bermejo PE, Oreja-Guevara C, Díez-Tejedor E. El dolor en la esclerosis múltiple: prevalencia, mecanismos, tipos y tratamientos. Rev Neurol 2010; 50: 101-8.
61. Bisogno T, Di Marzo V. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr Pharm Des 2008; 14: 2299-305.
62. Hill MN, Gorzalka BB. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 2009; 8: 451-8.
63. Beardsley PM, Thomas BF, McMahon LR. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. Int Rev Psychiatry 2009; 21: 134-42.
64. Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 2008; 4: 99-107.
65. Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol 2008; 20: 850-7.
66. Di Marzo V. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov Today 2008; 13: 1026-41.
67. Osei-Hyiaman D. Endocannabinoid system in cancer cachexia. Curr Opin Clin Nutr Metab Care 2007; 10: 443-8.
68. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008; 14: 2279-88.
69. Velasco G, Carracedo A, Blázquez C, Lorente M, Aguado T, Haro A, et al. Cannabinoids and gliomas. Mol Neurobiol 2007; 36: 60-7.
70. Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007; 28: 39-45.
71. Alonso-Alconada D, Álvarez A, Álvarez-Granda L, Hilario E. Potencial terapéutico del sistema endocannabinoide en la asfixia perinatal. Rev Neurol 2011; 53: 758-64.
72. Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M, et al; Pharmos TBI investigators. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006; 5: 38-45.
73. Cannabinoid use in progressive inflammatory brain disease (CUPID) (EudraCT 2005-002728-33). Coordinador: John Zajicek.
74. Neuroprotección por cannabinoides en la enfermedad de Huntington (EudraCT 2010-024227-24). Coordinador: Justo García de Yébenes.